BioGenCell
Stem Cell Therapy Platform for Degenerative Diseases
StartupBioGenCell is a Netanya-based startup in the Health Tech & Life Sciences sector, established in 2008. Stem Cell Therapy Platform for Degenerative Diseases. The company has raised a total of $18.35M across 4 funding rounds, currently at the Seed stage. BioGenCell was founded by Yael Porat, Eyal Peleg, Michael Belkin. Key investors include Marius Nacht. The company has 11-50 employees. Core technologies: Biologicals, Cells.
With $18.35M in total funding, BioGenCell is a Seed-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: Clinical Trial. The company holds 1 patent.
- StageSeed
- ProductClinical Trial
- ModelB2B
- Employees11-50
- HQNetanya
- DistrictCenter District
- Last Round$16M
- Marius NachtLead
Yael PoratCo-founder & CEO
Eyal PelegCo-founder & CFO
Michael BelkinCo-founder & CSO
10 articles covered by sources including www.prnewswire.com,
www.calcalistech.com,
biogencell.net,
www.firstwordpharma.com,
www.globes.co.il.
What does BioGenCell do?
BioGenCell is developing cellular therapies designed to treat blood flow problems in the limbs, a side effect of diabetes and heart disease. The company's technology creates autologous cells, derived from the patients themselves, to repair themselves. BioGenCell's lead product, BC1, uses the company's technology to treat blood vessel insufficiency, which can cause multiple organ failure in diabetic patients. Derived from the patient's own adult stem cells, BioGenCell's easy-to-use and cost-effective therapies can regenerate damaged tissues, with the eventual goal of treating a wide range of degenerative diseases including diabetes, heart failure, stroke, blindness, cancer, and immunological diseases. BioGenCell's patented technology platform provides a comprehensive solution for most aspects of cellular therapy and supports rapid manufacturing and long-term storage (biobanking) of therapeutic cellular products for use in patient treatment.
How much funding has BioGenCell raised?
BioGenCell has raised $18.35M in total funding across 4 rounds. The company is currently at the Seed stage. Key investors include Marius Nacht.
Who founded BioGenCell?
BioGenCell was founded in 2008 by Yael Porat (Co-founder & CEO), Eyal Peleg (Co-founder & CFO), Michael Belkin (Co-founder & CSO).
What sector is BioGenCell in?
BioGenCell operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Cells. Target customers: Healthcare & Life Sciences, Healthcare, Providers, Patients, Laboratories, Life Sciences, Biotechnology.
Where is BioGenCell located?
BioGenCell is based in Divrei Khayim Street 16, Netanya, Israel, Center District.